ABSTRACT
To date, various agents and molecules have been developed to treat post-stroke neuroinflammation; however, none of them are clinically successful. Post-stroke neuroinflammation is primarily attributed to microglial polarization as the generation of inflammasome complexes shifts microglia to their M1 phenotype and regulates the downstream cascade. Inosine, an adenosine derivative reported to maintain cellular energy homeostasis in stressed conditions. Although the exact mechanism is still unexplored, various studies have reported that it can stimulate axonal sprouting in different neurodegenerative diseases. Hence, our present study aims to decipher the molecular mechanism of inosine mediated neuroprotection by modulating inflammasome signaling towards altered microglial polarization in ischemic stroke. Inosine was administered intraperitoneally to male Sprague Dawley rats at 1 h post-ischemic stroke and was further evaluated for neurodeficit score, motor coordination and long-term neuroprotection. Brains were harvested for infarct size estimation, biochemical assays and molecular studies. Inosine administration at 1 h post ischemic stroke decreased infarct size, neurodeficit score, and improved motor co-ordination. Normalization of biochemical parameters were achieved in the treatment groups. Microglial polarization towards its anti-inflammatory phenotype and modulation of inflammation were evident by relevant gene and protein expression studies. The outcome provides preliminary evidence of inosine mediated alleviation of post-stroke neuroinflammation via modulation of microglial polarization towards its anti-inflammatory form through regulating the inflammasome activation.
Subject(s)
Ischemic Stroke , Stroke , Rats , Animals , Male , Microglia/metabolism , Inflammasomes/metabolism , Neuroinflammatory Diseases , Rats, Sprague-Dawley , Stroke/complications , Stroke/drug therapy , Stroke/metabolism , Anti-Inflammatory Agents , Ischemic Stroke/metabolism , InfarctionABSTRACT
Migraine headaches are usually intolerable, and a quick-relief treatment remains an unmet medical need. Almotriptan malate is a serotonin (5-HT1B/1D) receptor agonist approved for the treatment of acute migraine in adults. It is currently available in an oral tablet dosage form and has a Tmax of 1-3 h, and therefore, there is a medical need to develop a non-invasive rapidly acting formulation. We have developed an intranasal formulation of almotriptan malate using the quality-by-design (QbD) approach. A 2-factor 3-level full factorial design was selected to build up the experimental setting. The developed formulation was characterized for pH, viscosity, in vitro permeation, ex vivo permeation, and histopathological tolerance. To assess the potential of the developed formulation to produce a rapid onset of action following intranasal delivery, a pharmacokinetic study was performed in the Sprague-Dawley rat model and compared to the currently available marketed oral tablet formulation. For this, the LC-MS/MS bioanalytical method was developed and used for the determination of plasma almotriptan malate concentrations. Results of a pharmacokinetic study revealed that intranasal administration of optimized almotriptan malate formulation enabled an almost five-fold reduction in Tmax and about seven-fold increase in bioavailability in comparison to the currently available oral tablet formulation, suggesting the potential of developed almotriptan malate intranasal formulation in producing a rapid onset of action as well as enhanced bioavailability.
Subject(s)
Migraine Disorders , Serotonin Receptor Agonists , Animals , Rats , Administration, Intranasal , Chromatography, Liquid , Serotonin Receptor Agonists/pharmacokinetics , Rats, Sprague-Dawley , Tandem Mass Spectrometry , Tryptamines/pharmacokinetics , Migraine Disorders/drug therapy , Serotonin/therapeutic use , TabletsABSTRACT
Preparation of the biological samples is one of the most critical steps in sample analysis. In past decades, the liquid-liquid extraction technique has been used to extract the desired analytes from complex biological matrices. However, solid-phase extraction (SPE) gained popularity due to versatility, simplicity, selectivity, reproducibility, high sample recovery %, solvent economy, and time-saving nature. The superior extraction efficiency of SPE can be attributed to the development of advanced techniques, including the nanosorbents technology. The nanosorbent technology significantly simplified the sample preparation, improved the selectivity, diversified the application, and accelerated the sample analysis. This review critically expands on the to-date advancements reported in SPE with particular regards to the nanosorbent technology.
Subject(s)
Molecular Imprinting , Polymers , Reproducibility of Results , Solid Phase Extraction/methods , Solvents , Specimen Handling , Molecular Imprinting/methodsABSTRACT
Brexpiprazole (BRX) is approved for the treatment of schizophrenia and major depressive disorders and it is mainly metabolized by CYP3A4 and CYP2D6. Grapefruit juice (GFJ), pomegranate juice (PJ) and tomato juice (TJ) have the potential to inhibit CYP3A4 enzymes in the body. However, fruit juice-drug interactions between BRX and GFJ, PJ and TJ have not been studied extensively. The present study describes the influence of GFJ, PJ and TJ on the pharmacokinetic parameters of BRX in rats. The study samples were analyzed using a mass-accurate and single-step bioanalytical method by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry over a wide calibration range of 20-1,500 ng/ml. The results of the pharmacokinetic study denoted that the combined administration of GFJ and PJ could increase systemic exposure of BRX. The area under the curve of BRX increased 3.43- and 1.88-fold with co-administration of GFJ and PJ, respectively, while TJ with BRX had no effect on the area under the curve. Time to peak concentration and half-life were not significantly changed by any juice co-administration. The results show that GFJ and PJ affect the pharmacokinetic profile of BRX and hence advice needs to be given to patients.
Subject(s)
Chromatography, High Pressure Liquid/methods , Fruit and Vegetable Juices , Mass Spectrometry/methods , Quinolones , Thiophenes , Animals , Citrus paradisi/chemistry , Herb-Drug Interactions , Limit of Detection , Linear Models , Solanum lycopersicum/chemistry , Male , Pomegranate/chemistry , Quinolones/analysis , Quinolones/pharmacokinetics , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Thiophenes/analysis , Thiophenes/pharmacokineticsABSTRACT
Flibanserin (FLB) is the first United States Food and Drug Administration (USFDA) approved serotonin modulator recently marketed to treat acquired generalized women hypoactive sexual desire disorder. The scope of this study was to develop and validate a sensitive, selective and reliable ultra-performance liquid chromatography-mass spectroscopy/mass spectroscopy-based quantification method for FLB in rat plasma as well as brain tissue samples. The method includes a simple liquid-liquid sample extraction procedure. FLB was subjected to chromatographic separation using a poroshell C18 column with the mobile phase comprising a mixture of acetonitrile (ACN), 10 mM ammonium acetate and acetic acid (90:10:0.1, v/v/v). Detection and quantification of FLB after positive electrospray ionization were carried out in selective ion monitoring mode. The fragment ions (m/z) of FLB (parent ion: 391.1741) and IS (parent ion: 448.1550) were monitored at 161.0704 and 285.0917, respectively. A linear response of FLB was observed over a concentration range of 2.5-600 ng/mL in plasma and 5-500 ng/mL in brain tissue homogenate. The intra- and inter-day precision and accuracy of the method met the acceptable limits specified in the USFDA bioanalytical method validation guideline. The analyte was found to be stable in benchtop, freeze-thaw, auto-injector and dry extract stability studies. The developed method was used to quantitate FLB in the plasma and brain tissue of a single-dose oral pharmacokinetic and brain tissue distribution study in female rats. Maximum FLB concentration in plasma and brain was achieved within an hour; however, the total amount of the drug that reached the brain was significantly less than in plasma. Rate of elimination of FLB from brain was also faster resulting in a lesser half-life in brain compared to the plasma.
Subject(s)
Benzimidazoles/metabolism , Brain/metabolism , Animals , Female , Liquid-Liquid Extraction , Rats , Tandem Mass Spectrometry , Tissue DistributionABSTRACT
Empagliflozin (EGF) received USFDA approval in 2014 for oral use to control the glucose levels in adults with type 2 diabetes mellitus. Albeit, a systematic drug-excipient compatibility study of EGF has not been reported in the open literature. As physical and chemical interactions affect the performance of the formulation, this study intended to unveil the drug and excipients interactions which would later help in development of a robust solid dosage form. Differential scanning calorimetry (DSC) was applied as a screening tool for the assessment of compatibility between EGF and the list of excipients mentioned in the EMEA summary of product characteristics (SmPC)-section 6.1, along with mannitol and polyvinylpyrrolidone. Thermogravimetric analysis (TGA), Fourier Transform Infrared Spectroscopy (FTIR), X-ray Powder Diffraction (PXRD) and Hot Stage Microscopy (HSM) methods were utilized to appraise the interpretation of DSC results adequately. Isothermal stress testing (IST) studies of EGF were performed using the selected excipients to check the presence of interaction products (IPs) and the drug content by HPLC. Additional peaks were observed in the EGF-macrogol mixture than the drug peak in the HPLC analysis after two and half months, and those were separated and identified by the Ultra-High Performance Liquid Chromatography-Quadrupole Time of Flight Mass Spectrometry (UHPLC-QTOF-MS). Overall, EGF had shown compatibility with 13 selected excipients; however, initial observation of DSC and IST studies indicated plausible interaction of the EGF with macrogol.
Subject(s)
Benzhydryl Compounds/chemistry , Excipients/chemistry , Glucosides/chemistry , Calorimetry, Differential Scanning/methods , Chemistry, Pharmaceutical/methods , Chromatography, High Pressure Liquid/instrumentation , Dosage Forms , Mannitol/chemistry , Povidone/chemistry , Spectroscopy, Fourier Transform Infrared/methods , X-Ray Diffraction/methodsABSTRACT
Globally, Tephrosia purpurea (L.) Pers is used as an important component in herbal drug formulations for liver health. The present study is aimed to develop a suitable analytical approach for simultaneous analysis of three flavonoids (rutin, deguelin and rotenone) to establish quality control methods for plant. A novel High-performance liquid chromatography photodiode array detector (HPLC-PDA) method has been developed to quantify these flavonoids in T. purpurea. The method was validated, and data were subjected to chemometric analysis to select most optimal marker compound. The method that was found linear with R2 values ranges from 0.996 to 0.998 with good recoveries. Intra- and inter-day precision values were <2. HPLC analysis revealed high level of chemodiversity. Quantity of all the three chemical markers was found significantly disparate in samples from different locations. Deguelin was detectable only in three out of total eight samples. However, liquid chromatography-mass spectrometry analysis was found sufficiently sensitive to detect all the compounds in all samples. Thus, results suggest to apply combination of approaches to enhance confidence in chromatographic methods for quality control of herbal drugs. Principal component analysis ranked the markers as Rutin>Rotenone>Deguelin. This comprehensive approach employing multichromatography platforms can be successfully utilized in analysis of these bioactive markers and routine standardization of herbal material and formulations containing T. purpurea.
Subject(s)
Chromatography, High Pressure Liquid/methods , Flavonoids/analysis , Mass Spectrometry/methods , Plant Extracts/chemistry , Tephrosia , Biomarkers/analysis , Biomarkers/chemistry , Flavonoids/chemistry , Limit of Detection , Linear Models , Plant Extracts/standards , Principal Component Analysis , Reproducibility of ResultsABSTRACT
Metabolite identification is a crucial part of the drug discovery process. LC-MS/MS-based metabolite identification has gained widespread use, but the data acquired by the LC-MS/MS instrument is complex, and thus the interpretation of data becomes troublesome. Fortunately, advancements in data mining techniques have simplified the process of data interpretation with improved mass accuracy and provide a potentially selective, sensitive, accurate and comprehensive way for metabolite identification. In this review, we have discussed the targeted (extracted ion chromatogram, mass defect filter, product ion filter, neutral loss filter and isotope pattern filter) and untargeted (control sample comparison, background subtraction and metabolomic approaches) post-acquisition data mining techniques, which facilitate the drug metabolite identification. We have also discussed the importance of integrated data mining strategy.
Subject(s)
Data Mining/methods , Metabolomics , Pharmaceutical Preparations/metabolism , Tandem Mass Spectrometry , Chromatography, LiquidABSTRACT
Diacerein and aceclofenac are prescribed for reducing the symptoms associated with osteoarthritis. We present a simple HPLC method with UV detection for simultaneous determination of rhein (the immediate metabolite of diacerein) and aceclofenac from human plasma samples. Sample preparation was accomplished through liquid-liquid extraction with ethyl acetate and chromatographic separation was performed on a reversed-phase ODS column. Mobile phase consisted of a mixture of acetate buffer and acetonitrile run under gradient at flow rate of 1.0 ml/min. Wavelength was set at 258 nm. The method was validated for linearity, accuracy, precision and stability. The calibration was linear over the range of 0.1-7.0 microg/ml for rhein and 0.5-20 microg/ml for aceclofenac using 500 microl plasma samples. Extraction recoveries were 85% for rhein and 70% for aceclofenac. The method can easily be adopted for high-throughput clinical and pharmacokinetic studies of above two-drug fixed dose combination formulations.
Subject(s)
Anthraquinones/blood , Anti-Inflammatory Agents, Non-Steroidal/blood , Diclofenac/analogs & derivatives , Enzyme Inhibitors/blood , Calibration , Chromatography, High Pressure Liquid , Diclofenac/blood , Humans , Indicators and Reagents , Reproducibility of Results , Spectrophotometry, UltravioletABSTRACT
BACKGROUND: Dipyrone (metamizole) is a nonsteroidal anti-inflammatory drug used as an analgesic and antipyretic in both pediatric and adult patients. Dipyrone hydrolyses to 4-methylaminoantipyrine (MAA) in the stomach before absorption. There are several HPLC methods available for analysis of MAA from human plasma but no method has yet been developed on liquid chromatography-mass spectrometry (LC-MS) or LC tandem MS (LC-MS/MS), which are much more specific and sensitive techniques. METHODOLOGY: A high-performance LC-MS method for the quantification of 4-methylaminoantipyrine from human plasma has been developed, validated and applied to a pharmacokinetic study of 500 mg oral dose dipyrone. Following liquid-liquid extraction, the analyte was first separated on a reverse phase column using isocratic mobile phase and then analyzed by MS in selected ion monitoring mode using [M+H](+) ions, m/z 218.2 for 4-methylaminoantipyrine and 231.3 for 4-isopropylantipyrine (internal standard). RESULTS: The method exhibited a linear range from 0.2 to 10.0 µg/ml when only 100 µl human plasma sample was used. The lower limit of detection was 0.04 µg/ml (160 pg on column). The recovery was 80%. The accuracy and precision were obtained over the calibration curve range and were well within the limits specified under guidelines for bioanalytical method validation. The compound was stable under the experimental conditions. CONCLUSION: The method was demonstrated to be, simple, sensitive and rapid. It can be easily adopted in laboratories with access to LC-MS or MS/MS and applied to sample analysis in clinical settings where a large number of samples are generated.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/blood , Dipyrone/analogs & derivatives , Dipyrone/metabolism , Antipyrine/analogs & derivatives , Antipyrine/blood , Calibration , Chromatography, High Pressure Liquid , Chromatography, Liquid , Dipyrone/blood , Drug Stability , Humans , Mass Spectrometry , Reference Standards , Reproducibility of Results , Tandem Mass SpectrometryABSTRACT
A simple, precise and sensitive high performance liquid chromatography procedure has been developed for determination of carvedilol in human plasma. The method was developed on Lichrosphere R CN column using a mobile phase of acetonitrile/20 mM ammonium acetate buffer with 0.1% triethylamine (pH adjusted to 4.5) (40/60, v/v). The peaks were detected by using fluorescence detector (excitation wavelength 282 nm and emission wavelength 340 nm). Carvedilol and domperidone (internal standard) were extracted by liquid-liquid extraction procedure using dichloromethane. This method was specific and had a linearity range of 1-128 ng/ml with intra- and inter-day precision (%C.V.) less than 15%. The accuracy ranges from 87.3 to 100.88% and the recovery of carvedilol was 69.90%. The stability studies showed that carvedilol in human plasma was stable during short-term period for sample preparation and analysis. This method was used to assay the carvedilol in human plasma samples obtained from subjects who had been given an oral tablet of 12.5 mg carvedilol.